CD19 and acute lymphoblastic leukemia: 2018 Authorization: Approval extended to adult and pediatric (≧1month old) patients with CD19+ B-ALL in first or second complete remission exhibiting minimal residual disease (MRD) greater than or equal to 0.1%.